AbbVie Inc  

(Public, NYSE:ABBV)   Watch this stock  
Find more results for ABBV
97.45
+1.14 (1.18%)
Dec 15 - Close
NYSE real-time data - Disclaimer
Currency in USD
Range 96.64 - 97.88
52 week 59.27 - 98.87
Open 96.86
Vol / Avg. 11.56M/4.97M
Mkt cap 155.34B
P/E 23.67
Div/yield 0.71/2.91
EPS 4.12
Shares 1.60B
Beta 1.53
Inst. own 72%
Jan 25, 2018
Q4 2017 AbbVie Inc Earnings Release (Estimated) - 9:30AM EST - Add to calendar
Nov 29, 2017
AbbVie Inc at Evercore ISI Biopharma Catalyst/Deep Dive Conference - Webcast
Nov 16, 2017
AbbVie Inc at Jefferies Global Healthcare Conference - Webcast
Nov 8, 2017
AbbVie Inc at Credit Suisse Healthcare Conference
Oct 27, 2017
Q3 2017 AbbVie Inc Earnings Release
Oct 27, 2017
Q3 2017 AbbVie Inc Earnings Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '17) 2016
Net profit margin 23.32% 23.22%
Operating margin 38.67% 36.60%
EBITD margin - 42.09%
Return on average assets 9.63% 9.99%
Return on average equity 102.55% 138.05%
Employees 29,000 -
CDP Score - A-

Address

1 N Waukegan Rd
NORTH CHICAGO, IL 60064-1802
United States - Map
+1-847-9327900 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson's disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions. It offers products in various categories, including HUMIRA (adalimumab), Oncology products, Virology Products, Additional Virology products, Metabolics/Hormones products, Endocrinology products and other products, which include Duopa and Duodopa (carbidopa and levodopa), Anesthesia products and ZINBRYTA (daclizumab).

Officers and directors

Richard A. Gonzalez Chairman of the Board, Chief Executive Officer
Age: 63
Bio & Compensation  - Reuters
William J. Chase Executive Vice President, Chief Financial Officer
Age: 49
Bio & Compensation  - Reuters
Michael Severino M.D. Executive Vice President - Research & Development, Chief Scientific Officer
Age: 51
Bio & Compensation  - Reuters
Laura J. Schumacher Executive Vice President, External Affairs, General Counsel and Corporate Secretary
Age: 53
Bio & Compensation  - Reuters
Carlos Alban Executive Vice President - Commercial Operations
Age: 54
Bio & Compensation  - Reuters
Henry O. Gosebruch Executive Vice President, Chief Strategy Officer
Age: 44
Bio & Compensation  - Reuters
Timothy J. Richmond Senior Vice President - Human Resources
Age: 50
Bio & Compensation  - Reuters
Azita Saleki-Gerhardt Ph.D. Senior Vice President - Operations
Age: 53
Bio & Compensation  - Reuters
Robert A. Michael Vice President, Controller
Age: 46
Bio & Compensation  - Reuters
Robert J. Alpern M.D. Independent Director
Age: 66
Bio & Compensation  - Reuters